LEXEO and FUJIFILM Diosynth Biotechnologies Announce Gene Therapy Manufacturing Collaboration

Collaboration to enable manufacturing of AAV-mediated gene therapies for LEXEO’s upcoming clinical trials, future IND-enabling studies and commercialization

NEW YORK – October 13, 2021 – LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, and FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, today announced a strategic collaboration to support the development and manufacturing of LEXEO’s AAV-mediated gene therapies.